A Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of DVS SR for Treatment of Vasomotor Symptoms Associated With Menopause
Latest Information Update: 03 Aug 2012
Price :
$35 *
At a glance
- Drugs Desvenlafaxine (Primary)
- Indications Vasomotor symptoms
- Focus Adverse reactions; Therapeutic Use
- Sponsors Wyeth
- 23 Oct 2006 New trial record.